Show simple item record

dc.contributor.authorMorley, Kirsten C
dc.contributor.authorBaillie, Andrew
dc.contributor.authorVan Den Brink, Wim
dc.contributor.authorChitty, Kate E
dc.contributor.authorBrady, Kathleen
dc.contributor.authorBack, Sudie E
dc.contributor.authorSeth, Devanshi
dc.contributor.authorSutherland, Greg
dc.contributor.authorLeggio, Lorenzo
dc.contributor.authorHaber, Paul S
dc.date.accessioned2019-10-14T04:58:46Z
dc.date.available2019-10-14T04:58:46Z
dc.date.issued2018
dc.identifier.issn1354-3784
dc.identifier.doi10.1080/13543784.2018.1501471
dc.identifier.urihttp://hdl.handle.net/10072/388390
dc.description.abstractIntroduction: Alcoholic liver disease (ALD) is the leading cause of alcohol-related death and one of the most common forms of liver disease. Abstinence from alcohol is crucial to reducing morbidity and mortality associated with the disease. However, there are few pharmacotherapies for alcohol use disorder suitable for those with significant liver disease. Areas Covered: This paper presents a rationale for investigating the use of N-acetyl cysteine (NAC) to promote abstinence or reduce heavy alcohol consumption for patients with an alcohol use disorder, particularly in the presence of liver disease. NAC is an antioxidant with glutamatergic modulating and anti-inflammatory properties. Evidence is emerging that oxidative stress, neuro-inflammation and dysregulation of glutamatergic neurotransmission play a key role in alcohol use disorder. Similarly, oxidative stress is known to contribute to ALD. We outline the studies that have investigated NAC to reduce alcohol consumption including preclinical and clinical studies. We also review the evidence for NAC in other addictions as well as psychiatric and physical comorbidities associated with alcohol use disorders. Expert Opinion: NAC is low cost, well-tolerated and could have promise for the treatment of alcohol use disorder in the presence of liver disease. Clinical trials directly examining efficacy in this population are required.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherTaylor & Francis
dc.publisher.placeUnited Kingdom
dc.relation.ispartofpagefrom667
dc.relation.ispartofpageto675
dc.relation.ispartofissue8
dc.relation.ispartofjournalExpert Opinion on Investigational Drugs
dc.relation.ispartofvolume27
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences
dc.subject.fieldofresearchcode1115
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsPharmacology & Pharmacy
dc.subject.keywordsAlcoholic liver disease
dc.subject.keywordsN-acetyl cysteine
dc.titleN-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationMorley, KC; Baillie, A; Van Den Brink, W; Chitty, KE; Brady, K; Back, SE; Seth, D; Sutherland, G; Leggio, L; Haber, PS, N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research, Expert Opinion on Investigational Drugs, 2018, 27 (8), pp. 667-675
dc.date.updated2019-10-14T02:48:31Z
gro.hasfulltextNo Full Text
gro.griffith.authorSutherland, Greg T.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record